Yahoo奇摩 網頁搜尋

搜尋結果

  1. 2 December 2021; Oslo and Taipei: The Coalition for Epidemic Preparedness Innovations (CEPI) and Medigen Vaccine Biologics Corp. (MVC) will co-fund a clinical trial of heterologous and fractional booster doses – or 'mix-and-match' booster – combinations of MVC's COVID-19 vaccine, known as MVC-COV1901, with other COVID-19 vaccines.

  2. This trial was implemented by NTU Medical Hospital's National Center of Excellence for Clinical of Excellence for Clinical Trial & Research and led by Dr. Li-Min Huang. This clinical trial expects to recruit 365 subjects in four different age groups for vaccination.

  3. www.medigenvac.com › en › files2021 Annual Report

    MVC was also selected as the WHO Solidarity Trial Vaccines, which is led and funded by WHO, in the Philippines, Colombia, and in the Republic of Mali, the third phase clinical trial of the efficacy of the traditional placebo-controlled vaccine

  4. www.medigenvac.com › en › files2022 Annual Report

    1 Chapter 1. Letter to Shareholders I. 2022 Business Report (I)Implementation results of the 2022 business plan and profitability analysis MVC is a biopharmaceutical research and development company, and its main products include the Enterovirus 71 vaccine

  5. www.medigenvac.com › en › filesMeeting Handbook

    2023 Annual Shareholders’ Meeting Meeting Handbook Date: June 29, 2023 Place: R&D Center International Conference Hall, 2nd Floor, No. 8, Section 2, Shengyi Road, Zhubei City, Hsinchu County (This English version handbook is the translation of the Chinese

  1. 其他人也搜尋了